Industry news
- Industry news
- Oncology
News of the day
Publication of Phase II trial results of NGR-hTNF in liver cancer by the British Journal of Cancer
Milan (Italy), August 31, 2010 - MolMed S.p.A. (Milan:MLM) announces that the positive results of a phase II trial of its investigational anticancer drug NGR-hTNF in liver cancer have been published by the British Journal of Cancer (doi:10.1038/sj.bjc.6605858; published online, ahead of print). moreEISAI ANNOUNCES EXTENSION OF FDA REVIEW OF DRUG APPLICATION FOR INVESTIGATIONAL AGENT ERIBULIN MESYLATE
August 30, 2010 - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has received notification from the U.S. Food and Drug Administration (FDA) that the agency expects to complete priority review of the eribulin mesylate New Drug Application (NDA) for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act... moreSciBase successfully achieves clinical study objectives
August 30, 2010--Swedish medtech company SciBase is in the final stage of development with its unique method for first line detection of malignant melanoma. A clinical study has recently been completed involving 1200 patients and 200 malignant melanomas from 19 clinical centers in Sweden, Germany, UK, Hungary and Switzerland. Study data shows that targets are met with sensitivity (the ability to detect malignant melanoma) exceeding 98% and specificity (the ability to rule out malignant... moreIndustry news search
Most Viewed
Publication of Phase II trial results of NGR-hTNF in liver cancer by the British Journal of Cancer
Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety
SciBase successfully achieves clinical study objectives
TetraLogic Pharmaceuticals COMPLETES $32 Million SERIES C FINANCING
Recent news
To keep up to date with news from this category use our 
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
CAMBRIDGE, Mass.--August 27, 2010--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt,...
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
CAMBRIDGE, Mass., Aug 27, 2010 -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt,...
The Institute of Cancer Research and Horizon Discovery to Collaborate on Genome-wide Synthetic-lethality Screens
August 27, 2010 - The Institute of Cancer Research (ICR) and Horizon Discovery (Horizon) are forming a collaboration aimed at rapidly screening the human genome for novel drug targets that selectively kill cancer cells.
Hana Biosciences Reports Second Quarter 2010 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug 13, 2010 -- Hana Biosciences Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and...
Orphagen Pharmaceuticals Awarde Federal Grant for Adrenocortical and Prostate Cancer
San Diego, August 10, 2010 - Orphagen Pharmaceuticals announced today that the National Cancer Institute (NCI) has awarded a Phase I SBIR grant to the Company for development of a new class of small molecule drugs...
TetraLogic Pharmaceuticals COMPLETES $32 Million SERIES C FINANCING
Malvern, PA, August 10, 2010 - TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new...
Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety
Mainz, Germany, August 04, 2010 - A clinical first-in-human Phase I multi center study with GANYMED's monoclonal antibody iMAB362 demonstrated excellent safety up to a dosis of 1g/sqm in gastro-esophageal cancer...
The Gamida Cell-TEVA Joint Venture Receives FDA Fast Track Designation for StemEx
Jerusalem, Israel, June 21, 2010 --- Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow...
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us